Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

Thomas C. Wehler · Claudine Graf · Markus Möhler · Jutta Herzog · Martin R. Berger · Ines Gockel · Hauke Lang · Matthias Theobald · Peter R. Galle · Carl C. Schimanski

Published online: 20 September 2013
© Springer-Verlag Berlin Heidelberg 2013

Erratum to: J Cancer Res Clin Oncol
DOI 10.1007/s00432-013-1483-4

The corresponding author would like to correct the Figs. 1 and 2 and its captions, which were published incorrectly in the original version.

The corrected figures and captions are presented below.

The online version of the original article can be found under doi:10.1007/s00432-013-1483-4.

T. C. Wehler · C. Graf · M. Theobald
Third Department of Internal Medicine, Johannes Gutenberg University of Mainz, Mainz, Germany
e-mail: thomas.wehler@unimedizin-mainz.de

M. Möhler · P. R. Galle · C. C. Schimanski
First Department of Internal Medicine, Johannes Gutenberg University of Mainz, Mainz, Germany
e-mail: c.schimanski@marienhospital-darmstadt.de

J. Herzog · C. C. Schimanski
Department of Internal Medicine, Marienhospital Darmstadt, Martinspfad 72, 64285 Darmstadt, Germany

M. R. Berger
Toxicology and Chemotherapy Unit, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany

I. Gockel · H. Lang
Department of General and Abdominal Surgery, Johannes Gutenberg University of Mainz, Mainz, Germany
prophylactic skin protocol

- grade 0
  - cleansing syndet
  - topical metronidazole
  - oral doxycyclin (2x100 mg/d)

- grade I
  - topical corticoid
  - topical nadifloxacin

- grade II
  - cleansing syndet
  - topical metronidazole
  - oral minocyclin (2x50 mg/d)

- grade III
  - topical corticoid
  - topical nadifloxacin

reactive skin protocol

- grade 0
  - no specific therapy

- grade I
  - cleansing syndet
  - topical metronidazole

- grade II
  - oral minocyclin (2x50 mg/d)

- grade III
  - topical corticoid
  - topical nadifloxacin

Fig. 2 Prophylactic treatment regimen applied to group B and reactive treatment regimen applied to group C